$5.61
0.122.19%
At Close: -
$5.66
0.050.89%
After Hours: Jul 26, 7:19 PM EDT
15 minutes delayed
Comments
Loading...
ImmunityBio (NASDAQ:IBRX) Stock, Analyst Ratings, Price Targets, Forecasts
ImmunityBio Inc has a consensus price target of $7 based on the ratings of 2 analysts. The high is $8 issued by Jefferies on August 3, 2022. The low is $6 issued by Piper Sandler on April 29, 2024. The 3 most-recent analyst ratings were released by Piper Sandler on April 29, 2024, March 25, 2024, and May 12, 2023, respectively. With an average price target of $5 between Piper Sandler, there's an implied -11.66% downside for ImmunityBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Jefferies
1calculated from analyst ratings
Analyst Ratings for ImmunityBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/29/2024 | Buy Now | 6.01% | Piper Sandler | Joseph Catanzaro | $5 → $6 | Maintains | Neutral | Get Alert |
| 03/25/2024 | Buy Now | -11.66% | Piper Sandler | Joseph Catanzaro | $4 → $5 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | -29.33% | Piper Sandler | Joseph Catanzaro | $10 → $4 | Downgrade | Overweight → Neutral | Get Alert |
| 08/03/2022 | Buy Now | 41.34% | Jefferies | Kelly Shi | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ImmunityBio (IBRX) stock?
The latest price target for ImmunityBio (NASDAQ:IBRX) was reported by Piper Sandler on April 29, 2024. The analyst firm set a price target for $6.00 expecting IBRX to rise to within 12 months (a possible 6.01% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ImmunityBio (IBRX)?
The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by Piper Sandler, and ImmunityBio maintained their neutral rating.
When was the last upgrade for ImmunityBio (IBRX)?
There is no last upgrade for ImmunityBio
When was the last downgrade for ImmunityBio (IBRX)?
The last downgrade for ImmunityBio Inc happened on May 12, 2023 when Piper Sandler changed their price target from $10 to $4 for ImmunityBio Inc.
When is the next analyst rating going to be posted or updated for ImmunityBio (IBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on April 29, 2024 so you should expect the next rating to be made available sometime around April 29, 2025.
Is the Analyst Rating ImmunityBio (IBRX) correct?
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a maintained with a price target of $5.00 to $6.00. The current price ImmunityBio (IBRX) is trading at is $5.66, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.